¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Stickler syndrome, type III"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® carpal tunnel syndrome ÇÑ±Û ¼Õ¸ñ±¼ÁõÈıº
¼³¸í   
  ¼Õ¸ñ¿¡´Â ¾ÆÈ© °³ÀÇ ÈûÁÙ°ú ÇÑ °³ÀÇ ½Å°æÀÌ Åë°úÇϴ ±¼ÀÌ Àִµ¥ À̰÷À» ¼Õ¸ñ±¼À̶ó Çϰí, À̰÷À» Áö³ª´Â ½Å°æÀÌ ´­¸®¸é »õ±ú¼Õ°¡¶ôÀ» Á¦¿ÜÇÑ ³× ¼Õ°¡¶ôÀÌ ¾ÆÇÁ°í Àú¸° Áõ»óÀÌ´Ù. À̰ÍÀ» ¼Õ¸ñ±¼ÁõÈıºÀ̶ó ÇÑ´Ù. °Ë»ç ¹æ¹ýÀ¸·Î´Â ±ÙÀ° °Ë»ç¿Í ½Å°æÀü´Þ°Ë»ç°¡ ÀÖ´Ù. ½ÉÇÒ ¶§´Â ¾ÆÄ§À̳ª Àú³á¿¡ ¾ÆÆÄ¼­ ÀáÀ» ±ú°í ¼Õ¸ñ»Ó¸¸ ¾Æ´Ï¶ó ¾î±ú±îÁö ¾ÆÇÁ´Ù. ¼Õ¸ñÀ» ±ÁÈ÷°í ÀÖÀ¸¸é ÅëÁõÀÌ ½ÉÇÏ´Ù. ¼Õ¸ñÀ» ¹Ýº¹ÀûÀ¸·Î »ç¿ëÇϴ ¿îÀüÀÚ, °¡Á¤ÁÖºÎ, ¾Ç±â ¿¬ÁÖÀÚ, °øÀå¶óÀÎÀÇ ±Ù·ÎÀÚ, ÄÄÇ»ÅÍ »ç¿ëÀÚ, ¸ñ¼ö°¡ ÇØ´çµÈ´Ù. ¼Õ¹Ù´Ú»À°¡ ±úÁö°Å³ª ³Ñ¾îÁö¸é¼­ ¼Õ¹Ù´ÚÀ¸·Î Â¤¾úÀ» ¶§µµ ¹ß»ýÇϸ砵幰°Ô Áøµ¿Çϴ °ø±¸¸¦ »ç¿ëÇØµµ ³ªÅ¸³ª±âµµ ÇÑ´Ù. ÀÓ»êºÎ, Åëdz, ·ù¸¶Æ¼½º °üÀý¿°, °©»ó»ù ±â´É ÀúÇÏÁõ, ´ç´¢º´ µîÀÌ ÀÖÀ» ¶§ ÀÌ·± Áõ»óÀÌ ¿Ã ¼ö ÀÖ´Ù. ¿©ÀÚ¿¡°Ô ´õ ¸¹°í ÁַΠÀÚÁÖ ¾²´Â ¼Õ¸ñÀÌ ÇØ´çµÈ´Ù. ½ÉÇÒ ¶§´Â ¼Õ¸ñ¿¡ ¶¥ÄḸÇÑ Å©±â·Î ºÎ¾î¿À¸¥´Ù. ´©¸£¸é ¾ÈÀ¸·Î ¾¦ µé¾î°¡±âµµ ÇÏ°í ´Ù½Ã ¿òÁ÷ÀÌ¸é Æ¢¾î³ª¿Â´Ù. ¼Õ¸ñ»À ¿©´ü °³ Áß¿¡ ¹Ý´Þ»À¶ó ºÒ¸®´Â ÀÛÀº»ÀÀÇ Àδ밡 À̿ϵǾý±ä´Ù. ÅëÁõÀ» °¨¼ÒÇϴ ġ·á·Î ºÎ¸ñ, ¾óÀ½ÂòÁú, ÀÌ´¢Á¦, Ç×»ýÁ¦¸¦ »ç¿ëÇϱ⵵ Çϸç ÅëÁõÀÌ °è¼ÓµÇ¸é ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å È£¸£¸óÀ» ¼Õ¸ñºÎ¿¡ ÁÖ»çÇÏ¿© ÅëÁõÀ» ÁÙÀδÙ. ºÎÀÛ¿ëÀ¸·Î´Â Àç¹ß·üÀÌ ³ô´Ù. 
¿µ¹® sudden infant death syndrome ÇÑ±Û ¿µ¾Æ±Þ»çÁõÈıº
¼³¸í   
  ÇÑ »ì ÀÌÇÏÀÇ °Ç°­ÇÑ ¾Æ±â°¡ ¾Æ¹«·± Á¶ÁüÀ̳ª ¿øÀΠ¾øÀÌ °©Àڱ⠻ç¸ÁÇßÀ» °æ¿ì¿¡ ³»¸®´Â Áø´ÜÀÌ´Ù. ÀÌ ÁõÈıºÀº »ýÈÄ 1~4°³¿ù »çÀÌ¿¡ °¡Àå ¸¹ÀÌ ¹ß»ýÇϸç, ´ëºÎºÐ ¹ã 10½Ã¿¡¼­ ¿ÀÀü 10½Ã »çÀÌ¿¡ ¹ß»ýÇÑ´Ù. Á¶»êÇϰųª ºÎ¸ð°¡ Èí¿¬ÀÚÀÏ °æ¿ì, 20¼¼ ÀÌÇÏ »ê¸ðÀÇ ÃÊ»ê, ÀÓ½ÅÀü °Ç°­°ü¸®¿¡ ¼ÒȦÇÑ »ê¸ð¿¡°Ô¼­ Å¾ ¿µ¾Æ¿¡°Ô¼­ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. ÀÌ ÁõÈıºÀ¸·Î »ç¸ÁÇÑ ¿µ¾ÆÀÇ ÇüÁ¦ÀÏ °æ¿ì ÀϹÝÀûÀΠ¿µ¾Æº¸´Ù °É¸± È®·üÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼ºÈ£Èí±âº´À¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù.
¿µ¹® syndrome ÇÑ±Û ÁõÈıº
¼³¸í   
  Áõ»óÀÇ ÁýÇÕ. ¾î¶² Áúº´ÀǠ¡ÈÄÀÇ ÃÑÇÕÀ» ¸»ÇÑ´Ù. ´ë°³ ±× ¿øÀÎÀº ¾Ë ¼ö ¾øÀ¸³ª, Áõ»óÀÌ º¹ÇÕÀûÀ¸·Î ³ªÅ¸³ª°í ÀÌ¿¡ ´ëÇÑ Ä¡·á°¡ ÀÏÁ¤ÇÑ °æ¿ì ÇϳªÀÇ ÁõÈıºÀ¸·Î Ãë±ÞÇÑ´Ù.
¿µ¹® asphycitic syndrome ÇÑ±Û Áú½ÄÁõÈıº
¼³¸í   
  È£Èí±âÁßÀÇ »ê¼Ò°áÇÌ¿¡ ÀÇÇÑ »ý¸íÁ¤ÁöÀÇ Àý¹ÚÇÑ »óÅÂ, ¶Ç´Â ½ÇÁ¦·Î Á¤Áö°¡ ÀϾ »óÅÂ, °íÀÌ»êȭź¼ÒÁõ°ú Àú»ê¼ÒÁõ È¤Àº ¹«»ê¼ÒÁõ µîÀÌ µ¿¹ÝµÈ´Ù. ¿Ü°è ÆóÀÇ °íÅëÀÌ µÎÀýµÇ¾î ÆóÀǠȣÈíÀÛ¿ëÀÌ Àå¾ÖµÇ´Â °Í(¿ÜÁú½Ä)°ú °¡½º³ª ¾àÁ¦¿¡ ÀÇÇØ »ýü³» Á¶Á÷ÀÇ °¡½º±³È¯ÀÌ ¹æÇظ¦ ¹Þ´Â °Í(³»Áú½Ä)ÀÌ ÀÖ´Ù. ÀϹÝÀûÀ¸·Î ¿ÜÁú½ÄÀ» °¡¸®Å°´Â °æ¿ì°¡ ¸¹´Ù. ¿øÀÎÀ¸·Î¼­´Â ÄÚ³ª ÀÔ µî È£ÈíÀÔ±¸ÀÇ Æó»ö, À½½Ä¹°À̳ª À̹°¿¡ ÀÇÇÑ ±âµµÆó»ö, ¸ñÁ¶ÀÓ, ¹° ¶Ç´Â ºÐºñ¹° µîÀÌ ±âµµ·Î µé¾î°¡´Â °Í, ¾à¹° ¶Ç´Â ÆÄ»ódz¿¡ ÀÇÇѠȣÈí±Ù¸¶ºñ, ¸Å¸ô µî ¿Ü·Â¿¡ ÀÇÇѠȣÈí¿îµ¿ÀÇ ÀúÁö, °ø±â ÁßÀÇ »ê¼ÒºÎÁ· ¹× À¯µ¶°¡½ºÀÇ ÈíÀÔ µîÀ» µé ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • propagative type
    Áõ½ÄÇü
  • pyknic body type
    ´Ü½Åºñ¸¸½ÅüÇü
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • split-electrode-type probe
    ºÐÇÒÀü±Ø´õµëÀÚ
  • sthenic type
    ±Ù·ÂÇü
  • storage-type
    ÃàÀûÇü
  • swaged cast type crown
    ¾ÐÀÎÇü±Ý°ü
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü
  • simple type schizophrenia
    ´Ü¼øÇüÁ¤½ÅºÐ¿­º´
  • viral hepatitis type A
    AÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type B
    BÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type D
    DÇü¹ÙÀÌ·¯½º°£¿°
  • wild type
    ¾ß»ýÇü
  • wild type strain
    ¾ß»ýÁÖ
  • anginal syndrome
    Çù½ÉÁõÁõÈıº
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hemorrhagic fever with renal syndrome
    ÃâÇ÷¿­ÄáÆÏÁõÈıº
  • hepatorenal syndrome
    °£ÄáÆÏÁõÈıº
  • irritable bowel syndrome
    °ú¹Î´ëÀåÁõÈıº
  • Kallmann syndrome
    Ä®¸¸ÁõÈıº
  • Klinefelter's syndrome
    Ŭ¶óÀÎÆçÅÍÁõÈıº
  • Korsakoff's syndrome
    ÄÚ¸£»çÄÚÇÁÁõÈıº
  • locked-in syndrome
    °¨±ÝÁõÈıº
  • Mallory-Weiss syndrome
    ¸»·Î¸®¹ÙÀ̽ºÁõÈıº
  • Marfan syndrome
    ¸¶¸£ÆÇÁõÈıº
  • myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • nephritic syndrome
    ÄáÆÏ¿°ÁõÈıº
  • nephrotic syndrome
    ÄáÆÏÁõÈıº, ½ÅÁõÈıº
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • overuse syndrome
    °úµµ»ç¿ëÁõÈıº
  • paraneoplastic syndrome
    ½Å»ý¹°µþ¸²ÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • intuitive type
    Á÷°üÇü
  • lepromatous type
    ³ªº´Á¾Çü
  • leptosomatic type
    ¸¶¸¥Çü
  • mating type
    ±³¹èÇü
  • meromyarian type
    ºÎºÐ±ÙÀ°Çü
  • plaque-type mutation
    ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • nomenclatural type
    ºÐ·ùÇÐÀû±âÁظí
  • organic reaction type
    ±âÁú¹ÝÀÀÇü
  • ovulatory type
    ¹è¶õÇü
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • propagative type
    Áõ½ÄÇü
  • pyknic body type
    ºñ¸¸½ÅüÇü
  • split-electrode-type probe
    ºÐÇÒÀü±Ø´õµëÀÚ
  • storage-type
    ÃàÀûÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • RF coil type
    °íÁÖÆÄ ÄÚÀÏ À¯Çü
  • T-type channel
    T-Çü Åë·Î
  • aberrant type
    ÀÌÇü(ì¶úþ)
  • abortive type
    ºÎÀüÇü(ÝÕîïúþ).
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • agammaglobulinemia,x-linked, bruton type
    ¼º¿°»öü ¿¬°ü¼º, ºê·çÅæÇü(àõæøßäô÷ æáμàõ, ¡­úþ)
  • anovulatory type
    ¹«¹è¶õÇü
  • glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
  • golgi type i neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • golgi type ii neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • growth onset type diabetes
    Ãʱâ´ç´¢º´.
  • hebephrenic type
    ÆÄ°úÇü(÷òÍþúþ)
  • hemochorial type
    À¶Ç÷¸ðÇü(ëÖúìÙ¾úþ).
  • hemoglobin C type
    CÇü Ç÷»ö¼Ò
  • hemoglobin E type
    E Çü Ç÷»ö¼Ò
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • body type
    üÇü
  • body type
    üÇü(ô÷úþ).
  • bubble type vaporizer
    ±âÆ÷Çü ±âÈ­±â
  • calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
  • catatonic type
    ±äÀåÇü
  • cellular type dermatofibroma
    ¼¼Æ÷Çü ÇǺμ¶À¯Á¾
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • cryptogenic type
    ÀáÀçÇü(ËöËøÌ´).
  • cryptogenic type
    ÀáÀçÇü(íÖî¤úþ).
  • crystal type
    °áÁ¤Çü
  • culture, type
    Ç¥ÁرÕÁÖ, ±âÁØÁÖ
  • cyclicodevelopmental type
    ÁÖ±âÀû ¹ßÀ°Çü(ÊÙËÑËôÌ´).
  • cyclicopropagative type
    ÁÖ±âÀû Áõ½ÄÇü(ÊÙÌ¡ËàÌ´).
  • delayed type hypersensitivity
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹Î¹ÝÀÀ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Pneumocyte type I
    È£ÈíÇãÆÄ²Ê¸®¼¼Æ÷
    [¿¾ ¿ë¾î] È£Èí»óÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • type A hepatitis
    AÇü(úþ) °£¿°(ÊÜæú)
  • type A RNA virus
    AÇü(úþ) RNA ¹ÙÀÌ·¯½º
  • type B hepatitis
    BÇü(úþ) °£¿°(ÊÜæú)
  • type B RNA virus
    BÇü(úþ) RNA ¹ÙÀÌ·¯½º
  • type C virus
    CÇü(úþ) ¹ÙÀÌ·¯½º
  • type C RNA virus
    CÇü(úþ) RNA ¹ÙÀÌ·¯½º
  • type I error
    IÇü(úþ) ¿ÀÂ÷(è¦ó¬)
  • type II error
    IIÇü(úþ) ¿ÀÂ÷(è¦ó¬)
  • type I immunoglobulin
    IÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type II immunoglobulin
    IIÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type K immunoglobulin
    KÇü(úþ) ¸é¿ª(Øóæ¹) ±Û·ÎºÒ¸°
  • type L immunoglobulin
    LÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
  • Watson-Crick-type DNA
    ¿Ó½¼-Å©¸¯Çü(úþ) DNA
  • wild-type
    ¾ß»ýÇü(å¯ßæúþ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • medial medullary syndrome
    ³»Ãø¿¬¼öÁõÈıº
  • Meniere's syndrome
    ¸Þ´Ï¿¡¸£ÁõÈıº
  • middle lobe syndrome
    Áß¿±ÁõÈıº
  • mucocutaneous lymph node syndrome
    ÇǺÎÁ¡¸·¸²ÇÁÀýÁõÈıº
  • mucocutaneous ocular syndrome
    ÇǺÎÁ¡¸·¾ÈÁõÈıº
  • nephrotic syndrome
    ½ÅÁõÈıº, ³×ÇÁ·Î½Ã½ºÁõÈıº
  • omental adhesion syndrome
    ´ë¸Á¸·À¯ÂøÁõÈıº
  • overlap syndrome
    ÁßøÁõÈıº
  • Pancoast syndrome
    ÆÇÄÚ½ºÆ® ½Åµå·Ò
  • parietooccipital syndrome
    µÎÁ¤¿±Èĵο±ÁõÈıº
  • peutz-Jegher's syndrome
    Æ÷ÀÌÃ÷-¿¹°ÅÁõÈıº
  • PIE syndrome
    È£»ê±¸¼ºÆóħ½ÀÁõÈıº
  • Poland syndrome
    Æú¶õµåÁõÈıº
  • posterior interosseous syndrome
    Èİñ°£ÁõÈıº
  • postgastrectomy syndrome
    À§ÀýÁ¦ÈÄÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CS calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ...
PCS palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph...
TS Takayasu syndrome; Tay-Sachs; temperature sensitivity; temperature, skin; temporal stem; tensile str...
PPS Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc...
SBS shaken baby syndrome; short bowel syndrome; sick building syndrome; sinobronchial syndrome; small bo...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AP III Antipyrylazo III
apoLp-III Apolipophorin III
APO C-III Apolipoprotein C-III
AP III Atriopeptin III
CA III Carbonic anhydrase III
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • herpes simplex virus type 1
    Á¦1Çü ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º
  • herpes type I vaccine
    Á¦1Çü Æ÷Áø ¹é½Å
  • hinge type
    °æÃ¸Çü
    ÇϾǰñ ¿îµ¿.Áß ´Ü¼øÈ÷ °³±¸ ¶Ç´Â Æó±¸.¿îµ¿¸¸ ÇÏ´Â ÇüÅÂ.
  • HL-A type antigen
    ¿¡ÀÌÄ¡¿¤¿¡ÀÌ Ç׿ø
    »ç¶÷ÀÇ ÀûÇ÷±¸ ÀÌ¿ÜÀÇ ¸ðµç ¼¼Æ÷°¡ °¡Áö°í ÀÖ´Â Ç׿ø. »ç¶÷ ¹éÇ÷±¸ Ç׿øÀ̶ó°íµµ ÇÑ´Ù. H´Â »ç¶÷
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hutchinson-type neuroblastoma
    ÇãÄ£½¼Çü ½Å°æ¸ð¼¼Æ÷Á¾
  • hypocalcified type
    ¼®È¸È­ ºÎÀüÇü
  • immediate-type
    Áï½ÃÇü
  • intracanalicular type
    ¼Ò°ü³» Çü
  • iris-type
    ȫä ¸ð¾ç
  • Jaeger's test type
    ¿¹°Å ¹®ÀÚ
    ½Ã·Â °Ë»ç¿¡ »ç¿ëµÇ´Â ´ë¼ÒÀÇ ¹®ÀÚ¸¦ ´Ã¾î³õÀº Ç¥.
  • jealous type
    ÁúÅõÇü
  • knife edge type
    ³ªÀÌÇÁ ¿¡Âî ŸÀÔ
    finishing lineÀÇ ÀÏÁ¾ÀÌ´Ù.
  • lepromatous type
    ³ªÁ¾Çü
  • localized type
    ±¹¼ÒÇü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
RNA polymerase III <enzyme> A DNA-dependent RNA polymerase present in bacterial, plant, and animal cells. It functions in the nucleoplasmic structure where it transcribes DNA into RNA. It has specific requirements for cations and salt and has shown an intermediate sensitivity to alpha-amanitin in comparison to RNA polymerase I and II.
Registry number: EC 2.7.7.-
(12 Dec 1998)
phase III clinical trial <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments.
Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials.
(31 Dec 1997)
class III All other perennial streams not meeting higher class criteria.
(05 Dec 1998)
class III antigens Non-cell membrane molecules that are encoded by the S region of the major histocompatibility complex. These antigens are not involved in determining histocompatibility and include the complement proteins.
(05 Mar 2000)
class III malocclusion <dentistry> A Malocclusion where your lower teeth stick out past your upper teeth. This is also called an underbite.
(05 Mar 2000)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
mucolipidosis III <biochemistry> Mucolipidosis with mild Hurler-like symptoms, restricted joint mobility, short stature, mild mental retardation, and dysplastic skeletal changes, especially of the hip. Aortic and mitral valve disease are often present.
It is associated with a deficiency of UDP-N-acetyl glucosamine and lysosomal enzyme N-acetylglucosaminyl-1-phosphotransferase.
Inheritance: autosomal recessive.
Synonym: pseudo-Hurler polydystrophy, pseudopolydystrophy.
(05 Mar 2000)
mucopolysaccharidosis III Mucopolysaccharidosis characterised by heparitin sulfate in the urine, progressive mental retardation, mild dwarfism, and other skeletal disorders. There are four clinically indistinguishable but biochemically distinct forms, each due to a deficiency of a different enzyme.
(12 Dec 1998)
congenital antithrombin III deficiency Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream. Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III. The deficiency of antithrombin III will result in an increased risk for blood clot formation causing organ damage. This is an inherited as a autosomal dominant trait.
Inheritance: autosomal dominant.
(27 Sep 1997)
connective tissue activating peptide III Cytokine, produced from platelet basic protein, that acts as a growth factor.
(18 Nov 1997)
mycinamicin III O-methyltransferase <enzyme> Catalyses the incorporation of the methyl group of s-adenosyl-l-methionine at the 3'' position of mycinamicin III; from micromonospora griseorubida; genbank d16097
Registry number: EC 2.1.1.-
Synonym: mycf gene product, miii o-mtase
(26 Jun 1999)
cranial mononeuropathy III (compression type) A disorder involving vision changes and eyelid drooping associated with a decreased functioning of cranial nerve III. Damage is usually caused by compression of the nerves from localised lesions or a swelling in the area of the nerve.
Examples include cerebral aneurysms and tumours Symptoms include a drooping eyelid and double vision.
(diabetic type) A disorder involving vision changes and eyelid drooping associated with a decreased functioning of cranial nerve III as a complication of diabetes.
Symptoms include a drooping eyelid and double vision. Good control of blood sugars can reduce the incidence of this complication.
(27 Sep 1997)
cranial nerve III <anatomy, nerve> The occulomotor nerve is responsible for motor enervation of upper eyelid muscle, extraocular muscle and pupillary muscle.
Lesions of the oculomotor nerve results in ptosis (dropping eyelid), deviation of the eyeball outward, double vision and a dilated pupil.
Synonym: cranial nerve III.
(27 Sep 1997)
processus styloideus ossis metacarpalis III A pointed projection from the dorsolateral angle of the base of the third metacarpal bone; it sometimes exists as a separate ossicle.
Synonym: processus styloideus ossis metacarpalis III.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • type
    ŸÀÌÇÁ¶óÀÌÅÍ·Î Âï´Ù;(Ç÷¾×)ÇüÀ» °Ë»çÇÏ´Ù;»ó¡ÇÏ´Ù;...ÀÇ ÀüÇüÀÌ µÇ´Ù
  • type cast
    (±ØÁß Àι°ÀÇ ½ÅÀå,¸ñ¼Ò¸® µûÀ§¿¡ ¸Â´Â) ¹è¿ì¸¦ ¹è¿ªÇÏ´Ù
  • type founder
    ȰÀÚ ÁÖÁ¶°ø(¾÷ÀÚ)
  • type metal
    ȰÀÚ ÇÕ±Ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á